Friday, October 1, 2021  11:00am – 5:15pm EDT

Welcome and Program Introduction

SESSION 1: Local Therapies, Innovations and Adoption/Implementation
Lessons Learned from Positive and Negative Trials in Glioblastoma and Brain Metastasis
Roger Stupp, Christina Tsien, Vinai Gondi, In Ah Kim

Accepted Abstracts
Panel Discussion: Opportunities for Evaluating Local Therapies in the Management of CNS Malignancies
Moderator: Michael Vogelbaum; Panelists: Roger Stupp, Christina Tsien, Vinai Gondi, In Ah Kim, Rupesh Kotecha, Alireza Mansouri, Minesh Mehta, Gelareh Zadeh

BREAK

SESSION 2: Systemic Therapeutics: Lessons Learned from Past Experience
Changing Landscape for NSCLC BrMets: Beyond EGFR and ALK... – Sarah Goldberg
Targeted Therapy for GBM: How to Prioritize Targets and When is it Time to Move on? – Howard Colman

Accepted Abstracts
Panel Discussion: Use of Next Generation Sequencing in Care of Patients with Primary and Metastatic Brain Tumors
Moderators: Nancy Lin and Solmaz Sahebjam; Panelists: Carey Anders, Sarah Goldberg, Howard Colman, Martin van den Bent, Sara Hurvitz, Michael Weller

BREAK

SESSION 3: Immunotherapy: Hype and Hope
CAR T Cells in Primary Brain Tumors – Christine Brown
Oncolytic Viruses in Primary Brain Tumors – Maciej Lesniak
Checkpoint Blockade in Brain Metastases (current status and where it’s going) – Hussein Tawbi

Accepted Abstracts
Panel Discussion: Immunotherapy for Primary and Metastatic Brain Tumors: Hope or Hype
Moderators: Priscilla Brastianos and Peter Fecci; Panelists: Christine Brown, Maciej Lesniak, Hussein Tawbi, Evanthia Galanis, Mustafa Khasraw, Michael Platten, Jana Portnow

Town Hall: Transforming Patients from Subject to Partners
Chairs/Moderators: Mark Gilbert and Nancy Lin; Panelists: David Arons, Ralph DeVitto, Lianne Kraemer, J.C. & Luann Richardson, Terri Armstrong, Kathleen Wall, Evanthia Galanis, Minesh Mehta, Tatiana Prowell

Saturday, October 2, 2021  11:00am – 4:25pm EDT

Welcome

Keynote: Regulatory Considerations for the Treatment of CNS Tumors -- Past, Present and Future
Amy Barone, US Food and Drug Administration

SESSION 1: Neuroimaging
Imaging Endpoint of Subclinical Therapeutic Activity in Early Phase Clinical Trials for Brain Tumors – Benjamin Ellingson
Image Guided Intratumoral Delivery of Experimental Therapies and How to Evaluate Them in Clinical Trials?
Michael Vogelbaum

Accepted Abstracts
Panel Discussion: Advances in Neuroimaging: Integrating into Future Neuro-oncology Trials
Moderators: Mustafa Khasraw and Alireza Mansouri; Panelists: Benjamin Ellingson, Michael Vogelbaum, Jerrold Boxerman, Caroline Chung, Elisabeth de Vries, Patrick Wen
### SESSION 2: Integration of Supportive Care and Survivorship into Clinical Trials

- **Influence of Symptomatic and Supportive Care on Efficacy Endpoints in Clinical Trials: Myth or Reality** – Emilie Le Rhun
- **Assessing Clinical Benefit in CNS Tumor trials using Patient-Reported Outcomes** – Terri Armstrong
- **Assessing Clinical Benefit in CNS Clinical Trials -- Neurocognitive Function** – Jeffrey Wefel
- **Methodological Considerations When Including COAs into CNS Clinical Trials** – Linda Dirven

**Panel Discussion: Integration of Supportive Care in Clinical Practice and Research**
*Moderators: Susan Chang and Solmaz Sahebjam; Panelists: Emilie Le Rhun, Terri Armstrong, Linda Dirven, Jeffrey Wefel*

### SESSION 3: Clinical Research Methods in 21st Century

- **Precision Oncology Clinical Trial Designs That Integrate Biomarker Evaluation** – Mei-Yin C. Polley
- **RWE and External Control Arms in CNS Trials** – Rifaquat Rahman
- **Basket, Umbrella and Platform Trials in Neuro-oncology** – Evanthia Galanis

**Accepted Abstracts**

- **Are We Trying Hard Enough? Critique of Current Drug Development and Trial Designs in Neuro-oncology** – Steven Piantadosi

**Panel Discussion: Can We Conduct Better Clinical Trials in Neuro-oncology?**
*Moderators: Mustafa Khasraw and Hussein Tawbi; Panelists: Mei-Yin C. Polley, Rifaquat Rahman, Evanthia Galanis, Steven Piantadosi, Karla Ballman, John de Groot, Susan Geyer, Minesh Mehta, Patrick Wen, Alexandra Zimmer*

**Wrap up/Action Items**

- **Closing Remarks**

To view the full program [click here](#).